Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

M.W. Tang; S.Y. Rhee; S. Bertagnolio; N. Ford; S. Holmes; K.C. Sigaloff; R.L. Hamers; T.F. Rinke de Wit; H.J. Fleury; P.J. Kanki; K. Ruxrungtham; C.A. Hawkins; C.L. Wallis; W. Stevens; G.U. van Zyl; W. Manosuthi; M.C. Hosseinipour; N. Ngo-Giang-Huong; L. Belec; M. Peeters; A. Aghokeng; T. Bunupuradah; S. Burdah; P. Cane; G. Cappelli; C. Charpentier; A.Y. Dagnra; A.K. Deshpande; Z. El-Katib; S.H. Eshleman; J. Fokam; J.C. Gody; D. Katzenstein; D.D. Koyalta; J.J. Kumwenda; M. Lallemant; L. Lynen; V.C. Marconi; N.A. Margot; S. Moussa; T. Ndung'u; P.N. Nyambi; C. Orrell; J.M. Schapiro; R. Schuurman; S. Sirivichayakul; D. Smith; M. Zolfo; M.R. Jordan; R.W. Shafer

doi:10.1093/infdis/jit114

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

M.W. Tang, S.Y. Rhee, S. Bertagnolio, N. Ford, S. Holmes, K.C. Sigaloff, R.L. Hamers, T.F. Rinke de Wit, H.J. Fleury, P.J. Kanki, K. Ruxrungtham, C.A. Hawkins, C.L. Wallis, W. Stevens, G.U. van Zyl, W. Manosuthi, M.C. Hosseinipour, N. Ngo-Giang-Huong, L. Belec, M. PeetersA. Aghokeng, T. Bunupuradah, S. Burdah, P. Cane, G. Cappelli, C. Charpentier, A.Y. Dagnra, A.K. Deshpande, Z. El-Katib, S.H. Eshleman, J. Fokam, J.C. Gody, D. Katzenstein, D.D. Koyalta, J.J. Kumwenda, M. Lallemant, L. Lynen, V.C. Marconi, N.A. Margot, S. Moussa, T. Ndung'u, P.N. Nyambi, C. Orrell, J.M. Schapiro, R. Schuurman, S. Sirivichayakul, D. Smith, M. Zolfo, M.R. Jordan, R.W. Shafer

HIV and Tuberculosis

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Original language	English
Journal	Journal of Infectious Diseases
Volume	207
Issue number	S2
Pages (from-to)	S70-S77
ISSN	0022-1899
DOIs	https://doi.org/10.1093/infdis/jit114
Publication status	Published - 2013

Keywords

Viral diseases
HIV
AIDS
HAART
Antiretrovirals
First-line drugs
Mutations
Nucleoside
Reverse transcriptase inhibitors
Drug resistance
Stavudine
Zidovudine
Tenofovir
Efavirenz
Duration
Review of the literature

Access to Document

10.1093/infdis/jit114

http://lib.itg.be/pdf/itg/2013/2013jidi0S70.pdf

Cite this

Tang, M. W., Rhee, S. Y., Bertagnolio, S., Ford, N., Holmes, S., Sigaloff, K. C., Hamers, R. L., Rinke de Wit, T. F., Fleury, H. J., Kanki, P. J., Ruxrungtham, K., Hawkins, C. A., Wallis, C. L., Stevens, W., van Zyl, G. U., Manosuthi, W., Hosseinipour, M. C., Ngo-Giang-Huong, N., Belec, L., ... Shafer, R. W. (2013). Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. Journal of Infectious Diseases, 207(S2), S70-S77. https://doi.org/10.1093/infdis/jit114

@article{8cc12cb563a143b5b24abbae46452fd2,

title = "Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine",

keywords = "Viral diseases, HIV, AIDS, HAART, Antiretrovirals, First-line drugs, Mutations, Nucleoside, Reverse transcriptase inhibitors, Drug resistance, Stavudine, Zidovudine, Tenofovir, Efavirenz, Duration, Review of the literature",

author = "M.W. Tang and S.Y. Rhee and S. Bertagnolio and N. Ford and S. Holmes and K.C. Sigaloff and R.L. Hamers and {Rinke de Wit}, T.F. and H.J. Fleury and P.J. Kanki and K. Ruxrungtham and C.A. Hawkins and C.L. Wallis and W. Stevens and {van Zyl}, G.U. and W. Manosuthi and M.C. Hosseinipour and N. Ngo-Giang-Huong and L. Belec and M. Peeters and A. Aghokeng and T. Bunupuradah and S. Burdah and P. Cane and G. Cappelli and C. Charpentier and A.Y. Dagnra and A.K. Deshpande and Z. El-Katib and S.H. Eshleman and J. Fokam and J.C. Gody and D. Katzenstein and D.D. Koyalta and J.J. Kumwenda and M. Lallemant and L. Lynen and V.C. Marconi and N.A. Margot and S. Moussa and T. Ndung'u and P.N. Nyambi and C. Orrell and J.M. Schapiro and R. Schuurman and S. Sirivichayakul and D. Smith and M. Zolfo and M.R. Jordan and R.W. Shafer",

note = "PPU; ITG-C37A; ITG-C48A; DCS; U-INFDIS; JIF; DOI; PDF; DSPACE56",

year = "2013",

doi = "10.1093/infdis/jit114",

language = "English",

volume = "207",

pages = "S70--S77",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "S2",

}

Tang, MW, Rhee, SY, Bertagnolio, S, Ford, N, Holmes, S, Sigaloff, KC, Hamers, RL, Rinke de Wit, TF, Fleury, HJ, Kanki, PJ, Ruxrungtham, K, Hawkins, CA, Wallis, CL, Stevens, W, van Zyl, GU, Manosuthi, W, Hosseinipour, MC, Ngo-Giang-Huong, N, Belec, L, Peeters, M, Aghokeng, A, Bunupuradah, T, Burdah, S, Cane, P, Cappelli, G, Charpentier, C, Dagnra, AY, Deshpande, AK, El-Katib, Z, Eshleman, SH, Fokam, J, Gody, JC, Katzenstein, D, Koyalta, DD, Kumwenda, JJ, Lallemant, M, Lynen, L, Marconi, VC, Margot, NA, Moussa, S, Ndung'u, T, Nyambi, PN, Orrell, C, Schapiro, JM, Schuurman, R, Sirivichayakul, S, Smith, D, Zolfo, M, Jordan, MR & Shafer, RW 2013, 'Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine', Journal of Infectious Diseases, vol. 207, no. S2, pp. S70-S77. https://doi.org/10.1093/infdis/jit114

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. / Tang, M.W.; Rhee, S.Y.; Bertagnolio, S. et al.
In: Journal of Infectious Diseases, Vol. 207, No. S2, 2013, p. S70-S77.

Research output: Contribution to journal › A1: Web of Science-article › peer-review

TY - JOUR

T1 - Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

AU - Tang, M.W.

AU - Rhee, S.Y.

AU - Bertagnolio, S.

AU - Ford, N.

AU - Holmes, S.

AU - Sigaloff, K.C.

AU - Hamers, R.L.

AU - Rinke de Wit, T.F.

AU - Fleury, H.J.

AU - Kanki, P.J.

AU - Ruxrungtham, K.

AU - Hawkins, C.A.

AU - Wallis, C.L.

AU - Stevens, W.

AU - van Zyl, G.U.

AU - Manosuthi, W.

AU - Hosseinipour, M.C.

AU - Ngo-Giang-Huong, N.

AU - Belec, L.

AU - Peeters, M.

AU - Aghokeng, A.

AU - Bunupuradah, T.

AU - Burdah, S.

AU - Cane, P.

AU - Cappelli, G.

AU - Charpentier, C.

AU - Dagnra, A.Y.

AU - Deshpande, A.K.

AU - El-Katib, Z.

AU - Eshleman, S.H.

AU - Fokam, J.

AU - Gody, J.C.

AU - Katzenstein, D.

AU - Koyalta, D.D.

AU - Kumwenda, J.J.

AU - Lallemant, M.

AU - Lynen, L.

AU - Marconi, V.C.

AU - Margot, N.A.

AU - Moussa, S.

AU - Ndung'u, T.

AU - Nyambi, P.N.

AU - Orrell, C.

AU - Schapiro, J.M.

AU - Schuurman, R.

AU - Sirivichayakul, S.

AU - Smith, D.

AU - Zolfo, M.

AU - Jordan, M.R.

AU - Shafer, R.W.

N1 - PPU; ITG-C37A; ITG-C48A; DCS; U-INFDIS; JIF; DOI; PDF; DSPACE56

PY - 2013

Y1 - 2013

KW - Viral diseases

KW - HIV

KW - AIDS

KW - HAART

KW - Antiretrovirals

KW - First-line drugs

KW - Mutations

KW - Nucleoside

KW - Reverse transcriptase inhibitors

KW - Drug resistance

KW - Stavudine

KW - Zidovudine

KW - Tenofovir

KW - Efavirenz

KW - Duration

KW - Review of the literature

U2 - 10.1093/infdis/jit114

DO - 10.1093/infdis/jit114

M3 - A1: Web of Science-article

SN - 0022-1899

VL - 207

SP - S70-S77

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - S2

ER -